Navigation Links
Harbour Antibodies BV Signs Research and Licence Agreement With Lilly
Date:6/24/2011

ROTTERDAM, The Netherlands, June 24, 2011 /PRNewswire-iReach/ -- Harbour Antibodies BV, an Erasmus MC spin-off company,  announced today the completion of a non-exclusive research and licence agreement with Eli Lilly and Company ("Lilly"), a global pharmaceutical company, to generate and develop human therapeutic antibodies comprising immunoglobulin heavy and light chains(H2L2) using one of Harbour's transgenic mouse antibody discovery platforms.

Under the terms of the agreement Harbour will receive an upfront payment, success-based fees, and potential downstream product milestones and royalties. Specific financial terms were not disclosed.

"We are delighted to partner with Lilly," said Professor Frank Grosveld, The Head of Cell Biology and Genetics at ErasmusMC, and the Chief Scientific Officer of Harbour Antibodies BV. "Transgenic mice utilise the natural immune response and have proved over the last decade to be a very reliable route to discover potential human antibody based medicines. Recent industry acquisitions leave scope for new transgenic mouse platforms to meet the continuing clinical need for therapeutic antibody discovery. The Harbour H2L2 transgenic mouse platform will meet this need".

About Harbour Antibodies BV:

Harbour Antibodies BV was founded in December 2006 as a virtual company to commercialise transgenic mouse antibody platforms being developed at the Department of Cell Biology ErasmusMC.  In addition to the derivation of human H2L2 antibodies, transgenic mouse platforms have been developed for the derivation of novel second generation human and camelised human heavy chain only antibodies (HCAbs),  soluble human VH domains and  VH domain antibody complexes for use both as research tools and to meet unmet clinical need. The proprietary transgenic mouse platforms are protected by filed and granted patent applications in the major and the expanding healthcare markets. Harbour plans to partner broadly across the Pharmaceutical industry, and provide access to the transgenic mouse antibody platforms under MTA to academic partners where target antigens provided the basis of novel strategies for clinical intervention.

Further information on the Harbour technology platforms and management team can be found on the company's website at www.harbourantibodies.com or contact :

Roger Craig at r.craig@harbourantibodies.com     or

Bob Kamen at  r.kamen@harbourantibodies.com

For further information, please contact Sylvia Marmelstein, Press Officer Erasmus MC Tel:  +31 (0)10 703 5285 or E-mail s.marmelstein@erasmusmc.nl

About Erasmus MC and the Department of Cell Biology and Genetics:

The Erasmus Medical Center is situated in the centre of Rotterdam, the Netherlands and comprises the Academic Hospital and the Faculty of Medicine of the Erasmus University. It employs 13.000 people and is the largest medical centre in the country.

The Department of Cell Biology comprises a number of research groups that are primarily focussed on stem cell biology and developmental biology of mammals related to human disease. The regulation of transcription in vivo is a primary research focus. The Department boasts excellent genomics and proteomics facilities and has extensive experience in working with transgenic animals.

Media Contact: Roger Craig Harbour Antibodies, +31 (0)10 703 5285, r.craig@harbourantibodies.com


'/>"/>
SOURCE Harbour Antibodies BV
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies
2. Morphotek Receives Grant to Support Development of Therapeutic Antibodies against Biowarfare Agents
3. OriGene Releases 1500 TrueMABâ„¢ Monoclonal Antibodies
4. UNC-led team tests commonly used antibodies
5. Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
6. Diagenode Releases Two New Epigenetic Monoclonal 5-hmC Antibodies for Quantifying Global Hydroxymethylation
7. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
8. Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies
9. Michael J. Fox Foundation Offers High-Quality LRRK2 Antibodies for PD Therapeutic Development
10. OriGene Technologies Raises $16 Million to Build the Largest Collection of Next Generation Monoclonal Antibodies (TrueMAB(TM)) to Cover the Majority of Human Proteome
11. Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), ... products to treat rare diseases where there is an ... hosting an Investor Webcast Event Friday, December 16, 2016, ... defense regulators (IDRs) as a new drug class, as ... recently announced and published Phase 2 clinical data for ...
(Date:12/8/2016)... Dec. 8, 2016 Savannah River Remediation ... and selected NewTechBio,s NT-MAX Lake & Pond ... beneficial bacteria, in conjunction with Hexa Armor/ Rhombo ... with National Pollutant Discharge Elimination System requirements. ... a steady history of elevated pH levels, above ...
(Date:12/8/2016)... 8, 2016  Partnering to fuel Philadelphia,s ... Partners of Southeastern Pennsylvania (" ... company of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") ... for a $6 million funding initiative over a four ... Responding to a burgeoning economic vitality in digital ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... from its phase I/II dose escalation and expansion clinical trial for its lead ... Vienna, Austria. The purpose of the trial was to determine the safety, antitumor ...
Breaking Biology Technology:
(Date:12/6/2016)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the ... €500.0 million principal amount of its 1.414% senior unsecured notes ... senior unsecured notes due 2026. The closing ... subject to the satisfaction of customary closing conditions.  The notes ... The Company intends to use the net proceeds ...
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
(Date:11/30/2016)... WARSAW, Poland , Nov. 30, 2016 Not many of ... the most crucial aspects of recovery so we need to do it well. Inadequate ... including heart problems, high blood pressure, stroke, diabetes, and even cancer. Maybe ... find a Christmas present that could help them to manage their sleep quality? ... ...
Breaking Biology News(10 mins):